Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT
Bristol-Myers Squibb Australia Pty Ltd
Mild to moderate Alzheimer’s Disease
1 trial -
KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC, KarXT, KarXT
Bristol-Myers Squibb Australia Pty Ltd
Agitation Associated with Alzheimer’s Disease
1 trial -
KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC
Bristol-Myers Squibb Australia Pty Ltd
Mild to moderate Alzheimer’s Disease
1 trial -
KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT
Bristol-Myers Squibb Australia Pty Ltd
Agitation Associated with Alzheimer’s Disease
1 trial -
KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC
Bristol-Myers Squibb Australia Pty Ltd
Agitation Associated with Alzheimer’s Disease
1 trial -
KarXT, KarXT, KarXT, KarXT, KarXT, Placebo
Bristol-Myers Squibb Australia Pty Ltd
Psychosis Associated with Alzheimer’s Disease
1 trial -
Kerendia 10 mg film coated tablets, Placebo coated tablet 002 to bay 948862 coated tablet, Kerendia 20 mg film-coated tablets
The George Institute
Chronic Kidney Disease
1 trial -
Ketamine
United Therapeutics Europe Ltd
Chronic Pain
1 trial -
Ketamine Hydrochloride
United Therapeutics Europe Ltd
Traumatic Injury
1 trial -
Ketamine Hydrochloride
Camp4 Therapeutics Corp
Suicide
1 trial -
Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml
Disc Medicine
Non-psychotic therapy resistant unipolar depression
1 trial -
Ketorolac
The First People's Hospital of Lianyungang
Aortic Dissection
1 trial -
Keverprazan Hydrochloride tablets + high dose amoxicillin
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education
1 trial -
Khalas dates
United Therapeutics Europe Ltd
Diabetes Mellitus
1 trial -
Kreon 35 000 Ph. Eur. Lipase Einheiten, magensaftresistente Hartkapseln
Lacuna Pharma Pty Ltd
Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).
1 trial -
L-leucovorin
United Therapeutics Europe Ltd
Colorectal Cancer
1 trial -
LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR
Orchard Therapeutics (Netherlands) B.V.
Mucopolysaccharidosis type I, Hurler Syndrome
1 trial -
LDV/SOF
Gilead Sciences Ireland UC
Hepatitis C Virus
1 trial -
LECANEMAB
Eisai Co.,
Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid
1 trial -
LETROZOLE, ANASTROZOLE, CAPECITABINE, PACLITAXEL, CAPECITABINE, Verzenios 50 mg film-coated tablets, FULVESTRANT
Ningbo Cancer Hospital
Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement
1 trial -
LETROZOLE, Arimidex® 1 mg Filmtabletten, Camizestrant, ABEMACICLIB, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, Nolvadex® 20 mg Filmtabletten, EXEMESTANE
AstraZeneca AB
ER+/HER2- Early Breast Cancer
1 trial -
LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN
Ningbo Cancer Hospital
Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.
1 trial -
LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT
Stemline Therapeutics B.V.
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
1 trial -
LETROZOLE, EXEMESTANE, ANASTROZOLE, PALBOCICLIB, FULVESTRANT
Ningbo Cancer Hospital
ER+/HER2- metastatic breast cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources